Drug Update · Rare Disease

navepegritide (Yuviwel) FDA Approves for Achondroplasia: 1.5 cm/yr AGV Gain

August 20, 2026

Approval date

02/27/2026

Indication

To increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses

Primary efficacy result

1.5 cm/year increase in annualized growth velocity versus placebo at Week 52 (LS mean difference 1.5 cm/year; 95% CI 1.0, 1.9)

Pivotal trial

Trial 1 (APPROACH): randomized, double-blind, placebo-controlled 52-week period, N = 84 (navepegritide n = 57; placebo n = 27)

Dosing

Once-weekly subcutaneous, weight-based dosing per FDA label (Table 1) [see full prescribing information]

Clinical Perspective

Pediatric endocrinologists, clinical geneticists, and other clinicians managing children with achondroplasia will be the primary prescribers for YUVIWEL in patients aged 2 years and older with open epiphyses ^[1]^[5]. The randomized trial data support a measurable increase in annualized growth velocity (1.5 cm/year difference versus placebo at Week 52), which underlies the accelerated approval and the condition of confirmatory trials to verify effects on final adult height ^[1]^[5]^[2]. Will the required confirmatory trials verify an improvement in final adult height and long-term effects on disease-related complications and disproportionality measures?

Dr. Lakshmi Venkatesan, MBBS, MD (Paediatrics), DM (Medical Genetics) · Medical Genetics

The FDA approved YUVIWEL (navepegritide) for injection to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses on 02/27/2026 under accelerated approval based on an improvement in annualized growth velocity (AGV) demonstrated in a randomized trial showing a least-squares mean treatment difference in AGV of 1.5 cm/year versus placebo at Week 52 ^[2]^[1]^[5]^[4]. Continued approval may be contingent on confirmatory trials to verify clinical benefit, including effects on final adult height ^[1]^[2].

Clinical Context

YUVIWEL is a C-type natriuretic peptide (CNP) analog developed by Ascendis Pharma Growth Disorders A/S that is provided as a prodrug (navepegritide) releasing CNP and is administered by once-weekly subcutaneous injection ^[1]. Mechanistically, CNP released from navepegritide binds natriuretic peptide receptor-B (NPR-B), stimulates an increase in cyclic guanosine monophosphate (cGMP), signals through protein kinase G, and inhibits the mitogen activated protein kinase (MAPK) pathway to antagonize overactive FGFR3 signaling in achondroplasia, promoting chondrocyte differentiation and proliferation and thereby stimulating skeletal bone growth ^[1]. The product received accelerated approval and a rare pediatric disease priority review voucher; it has orphan designation for treatment of achondroplasia and marketing approval dated 02/27/2026 ^[3]^[2]. Dosing is weight-based and given once weekly; prescribers should review the full prescribing information for preparation and administration details ^[1].

Key Findings

Trial 1 (APPROACH) showed navepegritide increased annualized growth velocity (AGV) by 1.5 cm/year versus placebo at Week 52 (least-squares mean treatment difference 1.5 cm/year; 95% CI 1.0, 1.9) ^[1]^[5]^[4].
In Trial 1, navepegritide produced a least-squares mean increase from baseline in achondroplasia-specific height Z-score of 0.3 versus 0.0 for placebo (treatment difference 0.3; 95% CI 0.2, 0.4) at Week 52 ^[5]^[1].
The same analysis noted a least-squares mean treatment difference in CDC height Z-score of 0.3 (0.1, 0.5) at Week 52 ^[5]^[1].
Trial 1 enrolled 84 pediatric, treatment-naïve patients with genetically confirmed achondroplasia (navepegritide 0.1 mg/kg once weekly, n = 57; placebo, n = 27) in a 52-week randomized, double-blind, placebo-controlled period followed by a 52-week open-label extension; AGV was maintained among those who received 2 years of treatment in extension data reported to date ^[5]^[1]^[4].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Transient decreases in blood pressure have been reported with a once daily CNP analog; patients should be advised to contact their healthcare provider if they experience symptoms of decreased blood pressure while being treated with YUVIWEL ^[1].
Clinicians should consult current prescribing information for full dosing guidance.
Vomiting ^[1].
Injection-site reaction ^[1].
Pain in extremity ^[1].
Nausea ^[1].

Study Design

The effectiveness of YUVIWEL was established in Trial 1 (APPROACH), a randomized, double-blind, placebo-controlled 52-week period followed by a 52-week single-arm open-label extension that enrolled 84 pediatric, treatment-naïve patients with genetically confirmed achondroplasia (navepegritide 0.1 mg/kg once weekly, n = 57; placebo, n = 27); the primary efficacy endpoint was annualized growth velocity at Week 52 ^[5]^[1]^[4]. Clinicians should consult current prescribing information for full dosing guidance. A Phase 2 dose-finding randomized trial (Trial 2) also contributed longer-term open-label data ^[1]^[4]. The approval is an accelerated approval contingent on conduct of confirmatory postmarketing trials to assess final adult height and other long-term outcomes, per FDA requirements ^[2].

FAQ

Q1 What is YUVIWEL (navepegritide) approved for?

YUVIWEL is approved to increase linear growth in pediatric patients 2 years of age and older with achondroplasia who have open epiphyses. This indication was granted under accelerated approval based on an improvement in annualized growth velocity observed in a randomized trial; continued approval may depend on verification of clinical benefit in confirmatory trials assessing final adult height and other long-term outcomes.

Q2 How does navepegritide work?

Navepegritide is a prodrug that releases C-type natriuretic peptide (CNP). CNP binds to natriuretic peptide receptor-B (NPR-B), increases intracellular cyclic guanosine monophosphate (cGMP), signals through protein kinase G, and inhibits the mitogen activated protein kinase (MAPK) pathway, thereby antagonizing overactive FGFR3 signaling in achondroplasia and promoting chondrocyte differentiation and proliferation to stimulate skeletal bone growth.

Q3 What is the recommended dose of YUVIWEL?

YUVIWEL is administered once-weekly by subcutaneous injection with dosage based on body weight. Recommended weekly doses include 0.88 mg for 8 to 9.9 kg, 1.2 mg for 10 to 13.4 kg, 1.6 mg for 13.5 to 17.5 kg, 2.1 mg for 17.6 to 23 kg, 2.8 mg for 23.1 to 30.5 kg, 3.6 mg for 30.6 to 41.2 kg, 5 mg for 41.3 to 55.9 kg, 6.6 mg for 56 to 73.5 kg (use 2 kits; administer 0.6 mL from each kit), and 8.8 mg for 73.6 to 90 kg (use 2 kits; administer 0.8 mL from each kit). Refer to the full prescribing information for reconstitution, administration technique, site rotation, missed-dose guidance, and instructions for use. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects of YUVIWEL?

The most common adverse reactions reported (≥ 5%) include vomiting, injection-site reaction, pain in extremity, and nausea. Transient decreases in blood pressure have been reported with a once daily CNP analog; patients should be advised to contact their healthcare provider if they experience symptoms of decreased blood pressure. Safety in certain populations, such as those with moderate or severe renal impairment, is addressed in the prescribing information.

navepegritide (Yuviwel) FDA Approves for Achondroplasia: 1.5 cm/yr AGV Gain

Direct Clinical Takeaway & Evidence Summary

navepegritide (Yuviwel) FDA Approves for Achondroplasia: 1.5 cm/yr AGV Gain

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Rare Disease in your inbox.

Related Clinical Updates

FDA Approves marnetegragene autotemcel for LAD-I: 100% HSCT-free

FDA Approves Elamipretide for Barth Syndrome: 63 N Knee Strength Gain

FDA Approves KYGEVVI for TK2d: Cuts Death Risk 86%

Verified HCP Portal